Well, like I said, there is an element of suspicion surrounding these clinical results. The trial has been going for a while with great results along the way. its unfortunate for us all, however, I do feel that the team aren't going to accept this lightly and will investigate thoroughly until there is a valid reason for the formula to fail after passing.
Either the formulation made for the trial lost its efficacy, could have been stored incorrectly, there are many variables, and there is a deficiency there that needs to be corrected to replicate the formula that achieved the best results. A review of the formula is paramount right now and I hope Fre are running accelerated tests, for stability, and microbial using the formula made for these trials.
Or, like many are thinking, there is something amiss in the actual systemic area of the trial. I maintain that I think its good time to buy...
FRE Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
